6. Clinical laboratory testing including, but not limited to: CBC with differential and platelet count, total serum bilirubin, alkaline phosphatase, AST (SGOT), ALT (SGPT), serum creatinine, serum electrolytes, serum calcium and ser um albumin . NOTE: If clinical screening labs (CBC and Chemistry) were performed within 72 hours prior to the subject’s first immunotherapy, these labs are not required to be redrawn prior to the subject’s first immunotherapy. 7. Urine β-HCG (for women of child bearing potential) up to 72 hours prior to visit. 8. Whole blood and serum for baseline immunologic assays. 36 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol The following study evaluations will be performed on the same day post- immunotherapy : 1. Injection site reaction assessment within 30 -45 minutes after EP . 2. Review of adverse events. 3. Data should be downloaded from the EP device. 4.